COMPUTATIONAL BIOLOGY - NATURAL LANGUAGE PROCESSING - MACHINE LEARNING
BioXplor Discovery Software Suite
Data-Driven Drug Discovery
At BioXplor we are building an integrated drug discovery platform to accelerate discoveries and reduce failures. The integrated drug discovery platform combines internally developed models and datasets as well as externally developed models with public / private data. The knowledge discovery engine is powered by natural language processing and machine learning models to generate obvious and non-obvious biomedical knowledge on a topic from structured and unstructured data from public and private sources.
We have successfully applied the platform for Indication Expansion, Drug Repositioning, Pathway Analysis, Target ID, and Clinical Trial Responder ID / Personalized Medicine, with clients including top 5 pharma and biotech companies including Novartis, Merck and Bayer. BioXplor collaborates with academic teams for early stage drug discovery programs in oncology, including validation of predicted novel drug targets and novel drug designs in bioactivity assays and pre-clinical studies. BioXplor’s technology is available for licensing and we operate a CRO model.
BioXplor's knowledge-base consists billion's of structured sentences from over 30M biomedical publications, and over 250M structured sentences from 50K+ COVID-19 papers. These data are machine read using natural language processing and over 30 proprietary biomedical ontologies to uncover over 150M entity relationships between drugs, disease, genes, variants, pathway proteins, biological processes, tissues & cell types, co-morbidities, safety and toxicity issues. The entity relationship types include causation, protein-protein interactions, gene expression, mechanisms of action, and much more. BioXplor has structured content for 1000's of methods and applications, as well as instrumentation, research antibodies, recombinant proteins, ELISA assays, biochemicals, animal and cell models, and much more. For pharmaceuticals companies, BioXplor has collated all COVID-19 drugs in clinical trials, as well as all COVID-19 drugs with supporting evidence, and a predicted list of COVID-19 drugs and compounds. All Accessible via the Discovery Engines, API or custom projects.
Biomedical Knowledgebase
Lipedema Pathway Analysis for Novel Targets & Drug Repositioning Study
Cosentyx versus Etanercept Study on Super-Responders & Adverse Events
Drug Repositioning & Adverse Events Study for a Phase 3 Drug Trial Failure
Pancreatic Cancer Biomarker Study Generated Potential Novel Biomarkers
ACCESS CASE STUDIES HERE
PDL1 Biomarker Assay: Computer Aided Assay Design Study
Acute Lymphoid Leukemia Pathway Analysis & Drug Repositioning Study
Drug Discovery Case Studies
BioXplor was founded in January 2017 and is backed by UC Berkeley Skydeck, Merck & European Commission (EIC - Horizon 2020) accelerators, amongst other investment partners. The 10 person strong team has combined expertise in computer science and biomedical science applied to drug discovery, which are the core components of what we do, in equal measure. We are passionate about developing data-driven approaches to accelerate biomedical discoveries and to help reduce failures Life Science R&D.
Advisory Board: Dr. David Kwon, MD PhD (Harvard) MBA (UC Berkeley), former medical director at Novartis & Gilead, Prof. Jody Haigh, Haematology & Oncology, Department of Pharmacology and Therapeutics, University of Manitoba / CancerCare Manitoba, and Bill Allison, CTO at UC Berkeley.
Management Team: Mark Rogers, MSc (Molecular Biotech) is CEO and has a over 15 years experience in emerging biotechnology, previously Associate Director, Emerging Biotechnology Initiative at Merck KgaA. Pavel Kartasevs, MEng (Computer Engineering), MSc (Bioinformatics) is CTO, and has a specialised CompBio background combining high performance computing, bioinformatics and software engineering. Anna O'Leary, BA (Economics & Finance) is COO, and brings management, finance and business operations expertise to the team from Aramark and RBS Global Markets. John Conway, MSc (Data Science), is Head of Machine Learning at BioXplor, and brings over 20 years experience in hands-on analytics, data science and management in the Financial Industry to the team.
About Us
